Literature DB >> 15194598

Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy.

J A Gómez-Puerta, R Sanmartí, J R Rodríguez-Cros, J D Cañete.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15194598      PMCID： PMC1755079     

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  8 in total

1.  Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy.

Authors:  Christoph Strehblow; Guenther Haberhauer; Peter Fasching
Journal:  Wien Med Wochenschr       Date:  2010-05

Review 2.  Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors.

Authors:  Devesh Mewar; Anthony G Wilson
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.

Authors:  Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2007-07       Impact factor: 19.103

4.  An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab.

Authors:  P I Sidiropoulos; P Siakka; A Raptopoulou; M Mamoulaki; C Choulaki; H Koutala; H Kouroumali; H Kritikos; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

Review 5.  Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.

Authors:  Joseph R Lutt; Atul Deodhar
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors.

Authors:  Regina Rendas-Baum; Gene V Wallenstein; Tamas Koncz; Mark Kosinski; Min Yang; John Bradley; Samuel H Zwillich
Journal:  Arthritis Res Ther       Date:  2011-02-16       Impact factor: 5.156

7.  Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study.

Authors:  Takao Koike; Masayoshi Harigai; Shigeko Inokuma; Naoki Ishiguro; Junnosuke Ryu; Tsutomu Takeuchi; Yoshiya Tanaka; Hisashi Yamanaka; Koichi Fujii; Takunari Yoshinaga; Bruce Freundlich; Michio Suzukawa
Journal:  Rheumatol Int       Date:  2011-02-18       Impact factor: 2.631

8.  An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.

Authors:  Arie E van der Bijl; Ferdinand C Breedveld; Christian E Antoni; Joachim R Kalden; Sonja Kary; Gerd R Burmester; Christina Beckmann; Kristina Unnebrink; Hartmut Kupper
Journal:  Clin Rheumatol       Date:  2008-03-19       Impact factor: 2.980
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.